布地奈德联合特布他林雾化吸入治疗哮喘71例临床疗效观察

目的：观察布地奈德联合特布他林雾化吸入后患者症状的变化情况及治疗效果。方法：选择71例急性发作期支气管哮喘患者，并随机分为两组，其中35例为治疗组，另36例对照组。以7天一个疗程，对照组每日吸入布地奈德气雾剂，治疗组在吸入吸入布地奈德气雾剂之前，吸入一个疗程的布地奈德和特布他林雾化液。其他药品使用情况，两组均相同。结果：第4，8d症状评分显示，治疗组的急性发作期支气管哮喘患者较对照组明显降低，但第14天两组无明显差异。结论：在见效时间上，吸入布地奈德和特布他林雾化液有明显的优势，为门诊轻、中度急性发作期哮喘患者提供了首选药品。

Observation on clinical efficacy of 71 cases with asthma treated by budesonide and terbutaline inhalation

Objective：To observe the changes of patients＇ symptom condition after given treatment and the curative effect of budeso hide combined with terbutaline inhalation. Methods：71 cases of bronchial asthma in acute episode phase were selected and randomly divided into two groups, 35 cases in the treatment group and 36 cases in the control group, 7 days as a course. Patients in the control group were treated with budesonide aerosol everyday, while patients in the treatment group inhaled budesonide and terbutaline atomization for a course before given budesonide aerosol. For the application of other medicine, the two groups were same.Results：The scores on 4th, 8th showed that the patients of bronchial asthma in acute episode phase in the treatment group were obviously lower than the control group but no significant differences on 14th day.Conclusion：For the responding time, budesonide and terbutaline have distinct advantages which is the first choice for light and moderate acute asthma patients.